

Viral Pneumonia







Viral pneumonia: Not just for kids!



Viral Pneumonia

- Viruses recently recognized as important pathogens in CAP due to improved diagnostic tests (PCR)
- Cause of 2 35% of CAP in adults (more in kids)
- Recent emergence of new viral respiratory pathogens

Marcos MA, Esperatti M, and Torres A. Viral pneumonia. Curr Opin Infect Dis 22:143–147 Falsey An, Malsh EE. Viral pneumonia in older adults. Clin Infect Dis. 2006 Feb 15;42(4):518-24 Murray and Nadel's Textbook of Respiratory Medicine 5th Edition

Risk factors for viral PNA in adults

- Elderly: Higher rates of hospitalization and death from viral PNA in persons >60 yo
- COPD and asthma: frequently complicated by respiratory viral infections
- Immunocompromised pts at increased risk

Marcos MA, Esperatti M, and Torres A. Viral pneumonia. Curr Opin Infect Dis 22:143–147 Falsey Arc, Malsh EE. Viral pneumonia in older adults. Clin Infect Dis. 2006 Feb 15;42(4):518-24

Risk factors for viral PNA in adults

Table 1. Factors that contribute to severe respiratory infections associated with aging.

Respiratory factors Decreased respiratory muscle strength Decreased protective mucous level Decreased lung compliance Decreased levels of elastin and collagen in alveolar ducts Immune function Cellular immunity Decreased naive T cell count Increased memory T cell count Decreased T cell proliferation Imbalance of Th1 and Th2 responses Increased level of inflammatory mediators Humoral immunity Decreased B cell responses to new antigens Increased autoantibodies Innate immunity Decreased NK cell cytotoxicity Decreased NK cell response to IL-2 Increased TNF, IL-1, IL-6, and IL-8 levels

Clinical syndromes

- Upper respiratory tract (cold, pharyngitis, bronchitis)
- Bronchiolitis: acute inflammatory disorder of small airways
 - obstruction with air trapping, hyperinflation, wheezing.
 - \circ Most common < 2 yo
 - RSV most common, also human metapneumovirus, parainfluenza viruses, influenza A and B viruses, adenoviruses, measles virus, and rhinovirus
- Pneumonia
 - Similar presentation to bacterial PNA

Diagnosis

- Nasal swab specimens, nasal aspirates, or combined nose and throat swab specimens.
- Sputum, endotracheal aspirate samples, or BAL
- Rapid antigen detection, viral culture and PCR methods

Specific viral pathogens

Panel: Viruses linked to community-acquired pneumonia in children and adults

- Respiratory syncytial virus
- Rhinovirus
- Influenza A, B, and C viruses
- Human metapneumovirus
- Parainfluenza viruses types 1, 2, 3, and 4
- Human bocavirus*
- Coronavirus types 229E, OC43, NL63, HKU1, SARS
- Adenovirus
- Enteroviruses
- Varicella-zoster virus
- Hantavirus
- Parechoviruses
- Epstein-Barr virus
- Human herpesvirus 6 and 7
- Herpes simplex virus
- Mimivirus
- Cytomegalovirus†
- Measles†

*Mostly in children. †Mostly in developing countries.

Ruuskanen et al. Viral pneumonia. Lancet. 2011 Apr 9;377(9773):1264-75

- Annual winter epidemics x 6-8 wks (year round in tropics)
- Transmitted by small particle aerosols
- 2-3 day incubation period
- Max virus shedding is at onset of illness, continues for 5 to 7 days




Figure 3: Immunolocalisation of 2009 pandemic influenza H1N1 viral antigen in lung tissue

Viral antigens (red staining) are present in nuclei of alveolar-lining cells. Reprinted from reference 132 with permission of the American Society for Investigative Pathology.

Ruuskanen et al. Viral pneumonia. Lancet. 2011 Apr 9;377(9773):1264-75

Murray and Nadel's Textbook of Respiratory Medicine 5th Edition

Falsey AR, Walsh Schuleneumonia in older adults. Clin Infect Dis. 2006 Feb 15;42(4):518-24

Falsev AR, Walste

- Most common cause of viral PNA in adults
- family Orthomyxoviridae, Type A,B,C
- 2 envelope glycoproteins, Antigenic variation in H and N leads to epidemic nature
 - Hemagglutinin (H) initiates infectivity- binds to cell
 - Neuraminidase (N) protein cleaves new virus allowing spread

- Influenza pandemics occur when new viruses are introduced into the population
- Historic pandemics of 1918 (H1N1- 50 million deaths worldwide), 1957 (H1N1 and H2N2), 1968 (H3N2)
- Avian influenza H5N1 1997 outbreak, 58% with PNA
- Novel H1N1 influenza A virus emerged in Mexico and USA in Spring 2009
 - High risk populations: infants, young kids, healthy adults 20-40s, pregnant/postpartum women, immunocompromised, obesity, DM, COPD, asthma
 - Elderly less susceptible to H1N1 due to prior exposure
 - Mortality in hospitalized pts 7% –17%

- Each year, 300,000 hospitalizations (63% in >65 yo), and 36,000 deaths (85% in >65 yo) due to influenza
- 30% of pts hospitalized for influenza have **CXR** infiltrates
- secondary bacterial PNA in ? ~10%

Clinical manifestations


Falsey AR, Walsh

- Acute onset fever, chills, dry cough, dyspnea,
- Pharyngeal pain, nasal congestion
- HA, myalgias, malaise, anorexia, GI sxs
- Altered mental status (more in older persons)

Murray and Nadel's Textbook of Respiratory Medicine 5th Edition <u>Deconeumonia</u> in older adults. Clin Infect Dis. 2006 Feb 15;42(4):518-24

Imaging

 CXR may have bilateral reticulonodular infiltrates, sometimes lower zone predominant



Murray and Nadel's Textbook of Respiratory Medicine 5th Edition

- Secondary bacterial PNA
 - Mst common in elderly, or underlying pulm or cardiac dz
 - Period of improvement followed by increased cough, sputum production, and consolidation
 - Mst common Strep pneumo, then S. aureus and Grp A Strep

Treatment of Influenza

Vaccines:

- Inactivated virus vaccines: inactivated purified virions or partially purified HA and NA preparations
 - Efficacy 70% to 90% in healthy adults/children if good antigenic match
- Live, attenuated vaccine
 - More effective in children
 - In adults equal or less effective than inactivated vaccine
 - Contraindicated in pregnant or immunosuppressed

Treatment of Influenza

Antivirals

- reduce severity and duration of illness
- M2 inhibitors (M2Is) amantadine and rimantadine
- Only influenza A
- Neuraminidase inhibitors (NIs) oseltamivir and zanamivir
- both influenza A and B

Available treatment for influenza

Table 4. Administration characteristics of influenza antivirals and associated adverse effects.

Antiviral	Activity	Route of administration	Dosage (5 days)	Adverse effects
Amantidine	Influenza virus A	Oral	100 mg/day ^a	CNS and gastrointestinal events
Rimantadine	Influenza virus A	Oral	100 mg/day	Mild CNS and gastrointestinal events
Zanamivir Oseltamivir	Influenza viruses A and B Influenza viruses A and B	Inhaled Oral	2 Inhalations twice/day 75 mg twice/day ^a	Bronchospasm Mild gastrointestinal events

^a Dosage adjustment required with renal dysfunction.


522 · CID 2006:42 (15 February) · AGING AND INFECTIOUS DISEASE

Falsey AR, Walsh L. Tirs pneumonia in older adults. Clin Infect Dis. 2006 Feb 15;42(4):518-24

Respiratory syncytial virus (RSV)

- 2nd most common cause of viral PNA in older adults
- Common in winter (November April, peak Jan-Feb)
- Major cause of serious lower respiratory tract infections in young children
 - Primary RSV infection is nearly universal by age 2 and repeat infections are common due to incomplete immunity.
- Also important pathogen in adults, esp elderly, chronic lung disease, or immunocompromised
- Approx 10,000 deaths in persons > age 65 in the United States each year from RSV (2nd to influenza)

Coronavirus




Structural Protein	Function of Protein		
Nucleocapsid Protein (N)	 Bound to RNA genome to make up nucleocapsid 		
Spike Protein (S)	 Critical for binding of host cell receptors to facilitate entry of host cell 		
Envelope Protein (E)	 Interacts with M to form viral envelope 		
Membrane Protein (M)	 Central organiser of CoV assembly Determines shape of viral envelope 		
It has been noted that some CoVs d	It has been noted that some CoVs do not need to have the full ensemble of		

It has been noted that some CoVs do not need to have the full ensemble of structural proteins to make virions, highlighting that certain proteins may be dispensable or compensated by the function of non-structural proteins.


Coronavirus Emergence


Severe Acute Respiratory Syndrome (SARS-CoV)



- Identified in 2003, first infected humans in China in 2002
- Thought to be from bats, spread to civet cats to humans







- First identified in Saudi Arabia in 2012
- From dromedary camels to humans



Building a Safe, Secure and Resilient World Coronaviruses are a large family of viruses that are known to cause illness ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS).

 2019-novel coronavirus (COVID-19) was identified in Wuhan, China. This is a new coronavirus that has not been previously identified in humans.

COVID-19

- The virus that causes COVID-19 is known as SARS-CoV-2 It appears to have first emerged in Wuhan, China, in late 2019.
- The outbreak has since spread across China to other countries around the world. By the end of January, the new coronavirus had been declared a public health emergency of international concern by the WHO.
- The most commonly reported symptoms include a fever, dry cough and tiredness, and in mild cases people may get just a runny nose or a sore throat.
- In the most severe cases, people with the virus can develop difficulty breathing, and may ultimately experience organ failure. Some cases are fatal.
- > The virus causes Acute Respiratory Distress Syndrome (ARDS).



ACUTE LUNG INJURY ACUTE RESPIRATORY DISTRESS \$

ALI/ARDS is a clinical devastating syndrome that affects both medical and surgical patients.

Despite great advances in understanding the pathogenesis of disease, mortality rate is still high. Mortality rates ranges between 40– 60%, although some trials had demonstrated lower mortality rates

The Berlin definition of acute respiratory distress syndrome

Timing	Within 1 week of a known clinical insult, a new or worsening respiratory symptoms
Chest imaging ^a	Bilateral opacities — not fully explained by effusions, lobar/lung collapse, or nodules
	Respiratory failure not fully explained by cardiac failure or fluid overload.
Origin of edema	Need objective assessment (e.g., echocardiography) to exclude hydrostatic edema if no risk factor present
Oxygenation ^b	the patient's oxygen in arterial blood (PaO2) to the fraction of the oxygen in the inspired air (FiO2). These patients have a PaO2/FiO2 ratio of less than 300.

Clinical disorders associated with development of ALI/ARDS

Direct(Pulmonary)

Common

- Aspiration of gastric fluids
- Pneumonia

Less Common

- -Inhalation injury
- -Pulmonary contusion
 - -Fat embolism
- -Near Downing

Indirect(Extra pulmonary)

- Common
- Sepsis
- Severe trauma with prolonged hypotension
- Multiple Fractures

Less Common

- Acute pancreatitis
- Cardiopulmonary by pass
- Drug overdose
- DIC
- Burn
- Head injury

Direct

Pneumonia

Aspiration of gastric contents

Inhalational injury

Pulmonary contusion

Pulmonary vasculitis

Drowning

Indirect

Non-pulmonary sepsis

Major trauma

Pancreatitis

Severe burns

Non-cardiogenic shock

Drug overdose

Multiple transfusions or transfusion associated acute lung injury (TRALI)

Clinical picture

- dyspnea and hypoxemia,
- progressively worsens within hours to days, frequently requiring mechanical ventilation and intensive care unit-level care.
- The physical examination :
- Tachypnea and signs of respiratory distress
- Tachycardia, cyanosis, altered mental status
- Chest auscultation usually reveals rales, especially bibasilar

Complication

- Nosocomial pneumonia
- Multiple organ failure
- Deep venous thrombosis
- Gastrointestinal bleeding

Pathology of ALI/ARDS

The pathological features of ARDS are typically described as passing through three overlap
 Exudative phase.


- proliferative phase.
- Fibrotic phase.



High Permeability (non cardiogenic) pulmonary edema

- Disrupted alveolar-capillary membrane
- Membrane allows fluid to leak into the interstitial space
 Widened interstitial space

impairs diffusion





Investigation

- Chest-x ray: New, bilateral, diffuse, patchy or homogenous pulmonary infiltrate (pulmonary edema).
- Arterial blood gas: severity of hypoxemia.
- Echocardiography: exclude cardiogenic pulmonary edema
- Computed tomography: identify pulmonary cause; pneumonia or lung abscess or complication; pneumothorax, pleural effusion.

Investigations in patients with ALI or ARDS

Chest radiography: New, bilateral, diffuse, patchy, or homogeneous pulmonary infiltrates consistent with pulmonary oedema define both conditions.

Arterial blood gases: Indicate severity of hypoxaemia, defining acute lung injury and acute respiratory distress syndrome

Echocardiography: Helps to differentiate acute lung injury from cardiogenic pulmonary oedema

Computed tomography: Aids identification of pulmonary causes of acute lung injury (such as pneumonia, lung abscess) and detection of complications such as pneumothoraces and pleural effusions

Fibreoptic bronchoscopy with bronchoalveolar lavage: Helps to exclude infection, particularly in patients who are not improving despite treatmen

Therapeutic strategies

Treatment of patients with acute lung injury is essentially supportive, coupled with aggressive management of the precipitating condition.

General supportive measures
 Ventilatory treatment
 Nonventilatory treatments

- Nutrition
- Fluid therapy
- Corticosteroid
- Inhaled NO
- Exogenous surfactant
- Lung protective ventilatory strategy

THANK YOU